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Abstract
Background: Frameless image‑guided radiosurgery (IGRS) is a safe and effective 
noninvasive treatment for trigeminal neuralgia (TN). This study evaluates the use 
of frameless IGRS to treat patients with refractory TN.
Methods: We reviewed the records of 20 patients diagnosed with TN who 
underwent frameless IGRS treatments between March 2012 and December 2013. 
Facial pain was graded using the Barrow Neurological Institute (BNI) scoring 
system. The initial setup uncertainty from simulation to treatment and the patient 
intrafraction uncertainty were measured. The median follow‑up was 32 months.
Results: All patients’ pain was BNI Grade IV or V before the frameless IGRS 
treatment. The mean intrafraction shift was 0.43 mm (0.28–0.76 mm), and the 
maximum intrafraction shift was 0.95 mm (0.53–1.99 mm). At last follow‑up, 
8 (40%) patients no longer required medications (BNI 1 or 2), 11 (55%) patients 
were pain free but required medication (BNI 3), and 1 (5%) patient had no pain 
relief (BNI 5). Patients who did not have prior surgery had a higher odds ratio for 
pain relief compared to patients who had prior surgery (14.9, P = 0.0408).
Conclusions: Frameless IGRS provides comparable dosimetric and clinical 
outcomes to frame‑based SRS in a noninvasive fashion for patients with medically 
refractory TN.
Key Words: Frameless, image‑guided radiosurgery, radiation, stereotactic 
radiosurgery, trigeminal neuralgia
INTRODUCTION
Trigeminal neuralgia (TN) causes brief and severe 
intensity unilateral facial pain that is electric shock‑like, 
shooting, stabbing, or sharp in quality.[15] It occurs in one 
or more divisions of the trigeminal nerve, and there is no 
clinically evident neurological deficit.[15] Most cases of 
TN are produced by compression of the trigeminal nerve 
root within a few millimeters of entry into the pons, 
specifically the root entry zone.[20] Painful triggers include 
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chewing, brushing the teeth, wind on the face, or touching 
the face. It is more common in people >50 years and 
often affects women more than men.[23] The incidence 
of TN is approximately 5 new cases per 100,000 people 
annually.[9] Several schemes have been developed for 
the classification of trigeminal neuralgia, including the 
Barrow Neurological Institute (BNI) scoring system and 
the Burchiel classification scheme.[11,27]
The initial treatment of TN includes medical 
management with anticonvulsants and other 
medications, which are typically used for neuropathic 
pain. Approximately 90% of patients with new‑onset TN 
attain either complete or significant relief of symptoms 
following medical therapy.[23] While TN has been treated 
with invasive surgical techniques such as microvascular 
decompression,[25,28,36] radiofrequency rhizotomy,[3] and 
balloon compression,[2,17,31] stereotactic radiosurgery (SRS) 
has proven successful with its zero mortality and low 
morbidity.[29] However, radiosurgery has a lower likelihood 
of complete pain relief and a higher likelihood of 
pain recurrence compared with either microvascular 
decompression or percutaneous rhizotomy.[8] In 1951, 
Leksell reported the initial use of SRS for the treatment 
of TN.[19] Utilizing an orthovoltage X‑ray machine and 
stereotactic localization, this method offered long‑lasting 
pain relief without complications in two patients.
Traditional SRS treatment of TN has used a rigid 
invasive headframe to deliver between 80–90 Gy to a 
point within millimeters of the brainstem. We conducted 
a retrospective study of 20 patients who underwent 
frameless image‑guided radiosurgery (IGRS) by treating 
a point along the trigeminal nerve ranging from the 
dorsal root entry (DRE) zone to the retro Gasserian 
ganglion. This approach ensured submillimeter accuracy 
and allowed more complicated SRS planning over several 
days. We present our clinical findings and patient 
positioning data pertaining to the use of frameless 
IGRS using the BrainLAB Novalis ExacTrac system 
(BrainLAB AG, Feldkirchen, Germany) in the treatment 
of TN. The present study also compares the patient 
responses following the treatment for TN with frameless 
IGRS to frame‑based linear accelerator (LINAC) SRS 
based on historical published data.
MATERIAL AND METHODS
Patient population
Between March 2012 and December 2013, a total of 20 
individuals with TN underwent frameless IGRS at our 
institution. The Institutional Review Board approved 
the retrospective review of these cases. The primary 
characteristics of these patients are presented in Table 1. 
The median age was 73 years (range 52–85); there were 
8 males and 12 females. All patients were treated with 
medical therapy (e.g., carbamazepine, gabapentin, or 
baclofen) prior to the frameless IGRS. Four patients 
underwent a procedure for TN at another institution prior 
to the frameless IGRS: (1) One underwent a rhizotomy 
4 months before the SRS; (2) another had a microvascular 
decompression followed by two rhizotomies within 
28 months before the frameless IGRS; (3) one had 3 
gamma knife procedures, a microvascular decompression, 
and a rhizotomy within a 12‑year period before the 
frameless IGRS; and (4) another underwent 2 balloon 
rhizotomies before the frameless IGRS. Table 1 also 
highlights the lateralization of the TN, the division of the 
TN affected, and other comorbidities. One patient was 
diagnosed with multiple sclerosis. The median body mass 
index (BMI) of the patients was 27.1 (range 17.2–41.0).
All 20 patients were evaluated by a neurosurgeon, 
neurologist, and radiation oncologist and underwent 
frameless IGRS treatment. One patient underwent 
frameless IGRS retreatment after failing the first 
Table 1: Improvement in pain scores from the baseline to 
the last follow‑up of trigeminal neuralgia patients
Covariates N (%) Univariate Model




Male 8 (40) Reference
Female 12 (60) 1.20 [0.231, 6.218] 0.8290
Ever Smoke
Yes 10 (50) 3.235 [0.60,17.48] 0.1726
No 10 (50) Reference
Hypertension
Yes 11 (55) Reference
No 9 (45) 1.324 [0.261, 6.723] 0.7350
BMI 
<25 6 (30) Reference
25-30 8 (40) 1.268 [0.18,8.90] 0.8113
>30 6 (30) 1.000 [0.125, 8.00] 0.9999
Diabetes
Yes 5 (25) Reference
No 15 (75) 2.133 [0.321, 14.16] 0.4327
Hyperlipidemia
Yes 10 (50) 1.268 [0.252, 6.372] 0.7735
No 10 (50) Reference
Previous procedure for TN
Yes 4 (20) Reference
No 16 (80) 14.886 [1.119, 197.953] 0.0408
Laterality
Left 12 (60) Reference
Right 8 (40) 12.894 [1.665, 99.837] 0.0144
Distribution/Division
1 (V1; V1, V2; V1, V2, V3) 5 (25) Reference
2 (V2; V2, V3; V3) 15 (75) 1.158 [0.180, 7.446] 0.8773
BMI: Body mass index, TN: Trigeminal neuralgia
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treatment. Each patient was scored pre‑ and 
post‑ frameless IGRS based on the Barrow Neurological 
Institute (BNI) pain intensity scoring criteria (I: no pain; 
II: occasional pain, not requiring medication; III: some 
pain, controlled with medication; IV: some pain, not 
controlled with medication; V: severe pain/no pain 
relief).[6,27] All patients had a BNI of either IV or V prior 
to the initial frameless IGRS procedure.
Treatment method
Simulation
After each patient signed the informed consent, a 
bivalve‑style thermoplastic mask was fabricated to 
immobilize the head. All patients were simulated and 
treated supine and head‑first. Next, a stereotactic localizer 
frame was attached to the imaging frame, and then patients 
underwent a 0.6 mm axial slice computed tomography (CT) 
scan using 40‑slice Siemens Sensation Open (Siemens, 
Munich, Germany) from the vertex to the third cervical 
vertebra. We obtained a 0.5 mm constructive interference in 
a steady state (CISS) T2 magnetic resonance imaging (MRI) 
sequence using a three Tesla magnet with zero gantry tilt 
and registered the CT and MRI datasets using BrainLAB 
iPlan RT Image software, versions 4.1.0 and 4.1.1 [Figure 1].
Treatment planning
The affected side trigeminal nerve and organs at risk were 
contoured by the neurosurgeon and radiation oncologist 
on the fused dataset. The isocenter was placed in the 
retrogaussarian space. The SRS plan was prescribed at 
the isocenter, and all plans used between seven and nine 
non‑coplanar arcs with fixed diameter cones ranging from 
4.0 to 7.5 mm aperture, with total scatter factors of 0.669 
and 0.815, respectively. Each arc used between 60 and 
140 degrees. The mean maximum brainstem dose was 
31 Gy (range 8–57 Gy), the mean dose to 0.1 cc of the 
brainstem was 9 Gy (range 4–15 Gy), and the mean dose 
to 1 cc of the brainstem was 3 Gy (range 1–6 Gy).
Treatment delivery
Patients were placed in the simulation position on the 
LINAC treatment couch and the immobilization mask 
was applied. An optical tracking array for localization was 
used to determine the initial position. Stereoscopic X‑rays 
were fused with the digitally reconstructed radiographs 
from simulation, allowing Exactrac to measure the shift 
from simulation to treatment. Corrections to patient 
positioning were made for deviations exceeding 0.5 mm 
and 1° using a robotic couch with six degrees of freedom. 
The mean setup uncertainty from simulation to treatment 
was 2.9 mm (±1.5 mm). Before each arc was delivered, 
an additional set of stereoscopic X‑rays was obtained. 
Total treatment time ranged from 35 to 100 minutes. 
Three patients received 80 Gy, and 16 received 85 Gy. 
One patient was scheduled to receive 85 Gy, however, 
he experienced severe postnasal drip coupled with 
claustrophobia and was treated with 22.65 Gy.
Quality assurance
There were both LINAC and patient specific quality 
assurance measures taken to maximize the accuracy 
of treatment. The cones were commissioned with 
small‑field dosimetry techniques for treatment planning. 
Immediately prior to treatment delivery, a Winston–Lutz 
test was performed to verify that the treatment and 
imaging isocenter were congruent. The resulting 
root‑mean square geometric error was 0.58 ± 0.2 mm.
Follow‑up
Patients were assessed 1 month after the procedure and 
then approximately every 2 to 3 months. Each patient 
was evaluated by the treating neurosurgeon and/or 
radiation oncologist. A physical examination with facial 
sensation was performed, and a BNI score was assigned.
Data analysis
Primary data analyses were focused on assessing the 
outcome of change in BNI score from study entry to 
BNI measured at the last follow‑up. This score ranged 
from  −1  (change  from  4  to  a  5  in  1  patient)  to  a  4 
(in 3 patients going from a 5 down to a 1). This score 
change variable was used to create 3 categories of 
pain improvement: score change of 3 or 4 = marked 
improvement (n = 7 patients), score change of 
2 = moderate improvement (n = 7 patients), 
and  score  change  of  −1  or  1  =  some/none/worse 
improvement (n = 6). This 3‑level ordinal variable was 
then used as the outcome to assess whether variations in 
the outcome were due to clinical factors as determined 
by a proportional odds model using Statistical Analysis 
Software (SAS) V9.3. The proportional odds assumption 
was assessed using the score test and was not rejected 
for any of the covariates examined [Table 1] effectively 
leading to one odds ratio estimate that succinctly 
described marked or moderate improvement compared 
to some/none/worse improvement. Model goodness of fit 
Figure 1: (a and b) Thermoplastic mask used for patient 
immobilization. (c) The CISS MR utilized for target definition. The 
arrow depicts the dorsal root entry zone
c
ba
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was assessed using the deviance Chi‑square statistic, and 
was found to be adequate for each univariate model that 
was fit.
Descriptive analyses for the outcome and relevant 
covariates are reported as frequencies and 
percentage [Table 1]. Univariate model results are 
reported as odds ratio (OR) and 95% confidence 
limit (95% CI) as well as the P value [Table 1].
RESULTS
Between March 2012 and December 2013, a total of 
20 patients (12 women and 8 men) diagnosed with 
TN underwent frameless IGRS [Table 1]. The median 
age was 73 years (range 52–85 years). Twelve (60%) 
patients were treated for left‑sided pain, and 8 (40%) 
had right‑sided pain. The most common distribution 
of pain was V2 only (8 patients; 40%), followed by 
V2‑V3 (6 patients; 30%), V1 only (3 patients; 15%), 
and equal numbers of V3 only, V1‑V2, and V1‑V2‑V3 
(1 patient each; 5%). The median follow‑up for the 
20 patients was 32 months (range 21.6–41.2 months).
Intraprocedural positioning
Following initial alignment, repeat X‑rays were performed 
during the treatment delivery to verify that the patient 
position was maintained. The mean intrafraction shift was 
0.43 mm (0.28–0.76 mm), and the maximum intrafraction 
shift was 0.95 mm (0.53–1.99 mm) [Figure 2]. Rotational 
errors greater than 1 degree required correction with 
repositioning using the automated couch corrections and 
confirmatory stereoscopic X‑rays.
Outcomes
With a median follow‑up of 32 months, the response 
to the frameless IGRS treatment was based on the 
BNI score determined at follow‑up appointments 
with the neurosurgeon and/or radiation oncologist. 
Good‑to‑excellent results were defined as a BNI score of 
I–III. Of the 20 patients who underwent frameless IGRS 
evaluated at their last follow‑up, 1 (5%) patient had a 
post SRS BNI score of V due to failure of the frameless 
IGRS procedure. Eleven (55%) patients had a BNI of 
III as they continued to consume their TN medications 
following frameless SRS. One patient had occasional 
pain without needing medication and, therefore, was a 
BNI II. Seven (35%) patients scored a BNI of I as they 
had attained complete improvement of their symptoms 
and had discontinued all medications for TN. Thus, 
19 (95%) of the 20 patients had a BNI of III or less at 
last follow‑up.
The qualitative change in BNI score was marked in 7 (35%) 
patients, moderate in 7 (35%), and some/none/worse in 
6 (30%) patients. A univariate analysis was performed 
to determine if any clinical factors were associated with 
outcomes from SRS [Table 1]. Patients who did not 
have a prior surgery had increased odds for marked or 
moderate improvement compared to some/none/worse 
improvement by 14.9 times (P = 0.0408) compared to 
having had prior surgery. Having TN on the left side 
was associated with a 12.9 times (P = 0.0144) greater 
odds compared to the right side of either marked or 
moderate improvement compared to some/none/worse 
improvement in pain. Covariates having no effect on the 
odds for improvement include gender, smoking status, 
hypertension, BMI, diabetes status, hyperlipidemia status, 
and distribution/division (all P > 0.05).
Complications
No complications were reported by the TN patients. 
Physical examination performed by the neurosurgeon 
following the frameless IGRS procedure detected no new 
sensation or motor abnormalities.
Salvage treatments
Six patients required a salvage procedure after the 
frameless IGRS. Two underwent an MVD after the 
frameless IGRS. The first patient underwent the MVD 
1 month after the frameless IGRS and attained complete 
pain relief 7 months after the MVD. Nine months later, 
he experienced a recurrence of his facial pain requiring 
medications. He continued to consume medications at 
the last follow‑up 12 months later. Of note, this patient 
had undergone a rhizotomy prior to the frameless IGRS. 
Another patient underwent an MVD 13 months after the 
frameless IGRS and had complete pain relief 1 month 
later. One patient underwent a second frameless IGRS 
5 months after the first one, receiving 85 Gy at each 
procedure. He experienced complete pain relief 2 months 
later. Another patient had a rhizotomy 10 months after 
the initial frameless IGRS and continued to require 
antiepileptic medications at last follow‑up 22 months 
later. One patient underwent a rhizotomy 39 months 
Figure 2: Monitoring of the intrafraction motion during frameless 
IGRS. The mean intrafraction shift was 0.43 mm, and the mean 
maximum intrafraction shift was 0.95 mm
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after the initial frameless IGRS. Interestingly, this patient 
had undergone two rhizotomies and one MVD prior 
to the frameless IGRS. The final patient experienced 
increased pain following the frameless IGRS procedure 
and was treated with an increased dosage of antiepileptic 
medications.
The two additional patients who underwent a procedure 
for TN prior to the frameless IGRS were both assigned 
a BNI of III at the last follow‑up indicating that they 
continued to consume TN medications.
DISCUSSION
Since the advent of SRS techniques in the treatment 
of TN, the most common method utilized has been 
the gamma knife procedure.[10,14,21,22] Studies have shown 
that 77–95% of patients treated with gamma knife SRS 
have attained a benefit of at least a 50% reduction 
of pain.[4,16,22,27] LINAC SRS has emerged as a precise, 
effective, and noninvasive procedure for the treatment of 
TN.[29,32] LINAC SRS is dedicated for targeting within the 
central nervous system and offers stereotactically‑guided 
irradiation to the trigeminal nerve.[29]
The majority of LINAC SRS studies for TN have used 
a frame‑based system with either a Novalis, Varian, 
or Primus device,[7,12,13,18,24,26,29,30,35] whereas a few have 
reported the innovative frameless technique.[1,8] Table 2 
highlights myriad studies in the literature that utilized 
a linear accelerator SRS for the treatment of TN. Our 
study corresponds with previous studies in that the 
patients with TN failed to respond to previous medical 
therapy. The vast majority of patients attained either 
a good or excellent response to the treatment. The 
mean time to pain relief was approximately 4–8 weeks 
in most of the studies. The present study concurs with 
others that LINAC SRS is an effective and noninvasive 
treatment for patients with TN, especially in the older 
population. The median ages of the patients ranged 
52–85 years; the median age in the present study was 
73 years. It has been suggested that radiosurgery is an 
appealing option for older patients whose condition is 
not receptive to invasive surgical procedures.[29] LINAC 
SRS has proven successful, especially in patients who 
have not had a previous invasive treatment.[18] In their 
study of prognostic factors for radiosurgery treatment of 
TN, Chen et al. noted that sensitivity to anticonvulsant 
medication was the single most important prognostic 
indicator of treatment success for patients presenting 
with facial pain.[7] In the present study, patients who did 
not undergo prior surgery for TN had a higher odds ratio 
for marked or moderate pain relief compared to patients 
who had prior surgery (14.9, P = 0.0408). In addition, 
patients who had right‑sided TN had a higher odds ratio 
for marked or moderate improvement compared to those 
who had right‑sided TN (12.9, P = 0.0144). We found a 
significant difference that patients who underwent a prior 
procedure for TN had better outcomes. Coincidentally, 
all the patients with prior procedures had left‑sided 
(4 of 12 patients) TN and did worse. It is likely that the 
difference in outcome based on laterality is confounded 
by prior procedures.
Frameless radiosurgery has recently gained in popularity 
because it is a true noninvasive procedure without the 
need for anesthetics and sterile processing.[8] In addition, 
the frameless system avoids patient discomfort associated 
with frame application and is able to treat extracranial 
lesions.[5] The frameless approach corrects for positioning 
errors automatically due to the imaging guidance during 
the procedure.[8] The imaging, planning, and treatment 
components may be performed in different sessions. In 
this respect, frameless SRS is valuable in developing more 
complicated SRS planning over a several day period. 
Studies utilizing a head phantom have shown that 
intrafraction motion in the BrainLab frameless mask is 
minimal[33] and that this innovative technique is valuable 
in treating intracranial benign and malignant lesions.[34]
Frameless IGRS has rarely been used to treat TN.[8] 
Chen et al. performed a study of 44 patients who 
Table 2: SRS using linear accelerator for the treatment of trigeminal neuralgia
Study N Dose/Device Follow‑Up 
(Months)
% Good or Excellent 
response
Goss et al. 2003 25 90 Gy/Novalis 18 (8-52) 100
Frighetto et al. 2004 22 70-90 Gy/Novalis 21.2 (8-52) 95.4
Kubicek et al. 2004 20 (23 treatments) 82.3-100 Gy/Varian 56.5 78
Richards et al. 2005 28 80 Gy/Varian 12 (1-40) 75
Pusztaszeri et al. 2007 17 40-56 Gy/Primus 12 (1-60) 100
Chen et al. 2010 44 90 Gy/Novalis* 15 91
Chen et al. 2008 82 85-90 Gy/Novalis 18 85.3
Zahra et al. 2009 20 90 Gy/Novalis 14.2 95
Smith et al. 2011 179 70-90 Gy/ 28.8 (5-142) 79.3
Current Study 2017 20 (21 treatments) 80-85 Gy/Novalis* 32 95
*Indicates frameless image-guided radiosurgery using Novalis linear accelerator with ExacTrac
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were treated with frameless IGRS over an 18‑month 
period.[8] The isocenter dose of 90 Gy was delivered 
via a 4‑mm collimator. The median age of patients was 
65 years, and their BNI scores were IV or V prior to the 
procedure. Before the day of the treatment, the patients 
underwent high‑resolution MRI with a 1.0 mm slice 
thickness. The overall intrafraction positioning error was 
0.49 ± 0.44 mm, and the median time to pain relief was 
4 weeks. A total of 40 (91%) patients attained a BNI 
score of III or better, whereas 19 (43%) patients achieved 
a BNI score of I.
The findings of the present study concur with those of 
Chen et al. using frameless IGRS to treat patients with 
TN.[8] Our patient population was slightly older than 
those of Chen et al. (73 vs 65 years), while the BNI scores 
in both studies were either IV or V prior to the procedure. 
The MRIs in our study were performed with a 0.6 mm 
slice thickness which allowed better visualization of the 
area and greater precision in treatment compared to the 
work of Chen et al. who used a 1.0 mm slice thickness. 
The mean intrafraction shift in our study was 0.43 mm 
compared to 0.49 mm in theirs. Nineteen (95%) patients 
received a BNI score of III or better following frameless 
IGRS in the current study, and 8 (40%) patients attained 
complete pain relief with a BNI score of I.
CONCLUSION
The present study describes our initial experience with 
treatment of TN using a frameless IGRS procedure in 
a multidisciplinary setting. Our data suggest that it is 
an effective and noninvasive method of treating TN, 
especially in older individuals who are refractory to 
medical management. The slice thickness of 0.6 mm 
provided increased resolution at the target compared to 
previous studies in the literature. This small thickness 
coupled with the mapping of the patient’s movement 
during treatment allowed us to have a greater confidence 
to perform frameless IGRS. Further investigation is 
warranted with a larger sample size to confirm the 
efficacy of frameless IGRS for TN.
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